Ekso Bionics Announces EGM Builders as First Customer to Adopt EVO Technology
October 29 2020 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced that EGM Builders, a
self-performing general contractor providing construction services
in New Jersey and New York, is the first customer to acquire
EVO™ units. Launched in August 2020, EVO is the Company’s
latest innovation in exoskeleton technology for industrial use.
“Physical fatigue can have significant and
negative impacts on employees and companies, as it leads to
injuries that can have long-term consequences for individuals and
reduce productivity,” said Michael Pratt, Vice President at Ekso
Bionics. “As a company focused on protecting and enhancing human
strength, endurance and mobility, innovating technologies, such as
EVO, that reduce fatigue for industrial workers is a priority. With
its early adoption of EVO, EGM Builders is demonstrating its own
commitment to protecting the well-being of its valued
employees.”
EVO, the next generation of Ekso’s upper-body
exoskeleton for industrial use, is the world’s most durable,
assistive, and naturally-tracking vest of its kind. EVO includes
additional technology, based on market feedback, to aid workers
with overhead work, reduce fatigue, and lower the risk of shoulder
and back muscle strain. EVO offers 5 to 15 pounds of lift
assistance in each arm to elevate and alleviate the day-to-day
strain on workers across all industries.
“Commercial construction is physically demanding
work and maintaining employee physical health is of our utmost
importance,” said Michael Espinosa, President & CEO, Partner at
EGM Builders. “We are committed to protecting the safety and health
of our employees, who are our most valuable asset and critical
resource. EVO’s unique technology will allow our dedicated team
members to stay safe and comfortable while performing the
industry-leading work for which EGM Builders is known. Reducing the
risk of workplace injuries is essential for ensuring that we can
attract and retain the best industrial construction workers in the
region while sustaining the morale that brings out our employees’
dedication to excellence.”
About Ekso
Bionics®Ekso Bionics® is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical and industrial applications. Founded in 2005, the Company
continues to build upon its industry-leading expertise to design
some of the most cutting-edge, innovative wearable robots available
on the market. Ekso Bionics is the only exoskeleton company to
offer technologies that range from helping those with paralysis to
stand up and walk, to enhancing human capabilities on job sites
across the globe. The Company is headquartered in the San Francisco
Bay Area and is listed on the Nasdaq Capital Market under the
symbol “EKSO.” For more information, visit: www.eksobionics.com or
follow @EksoBionics on Twitter.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the potential benefits, performance and
effectiveness of the Company’s products and systems, including EVO.
Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company’s
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company’s inability to obtain
adequate financing or maintain operating revenues (including as a
result of the COVID-19 pandemic) to fund the Company’s operations
and necessary to develop or enhance the Company’s technology, the
significant length of time and resources associated with the
development of the Company’s products, the Company’s failure to
achieve broad market acceptance of the Company’s products, the
failure of the Company’s sales and marketing efforts or of partners
to market the Company’s products effectively, adverse results in
future clinical studies of the Company’s medical device products,
the failure to obtain or maintain patent protection for the
Company’s technology, the failure of the Company to obtain or
maintain regulatory approval to market the Company’s medical
devices, disruptions in the Company’s supply chain due to the
outbreak of the COVID-19 virus and other delays that may result
from the COVID-19 pandemic, the Company’s lack of product
diversification, existing or increased competition, and the
Company’s failure to implement the Company’s business plans or
strategies. These and other factors are identified and described in
more detail in the Company’s filings with the U.S. Securities and
Exchange Commission. To learn more about Ekso Bionics please visit
the Company’s website at www.eksobionics.com or follow @EksoBionics
on Twitter. The Company does not undertake to update these
forward-looking statements.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024